SCHEMBL13611400

SCHEMBL13611400

COC(=O)C(CNC(C)=O)NC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41
PTGS2 P35354 1/20 0.41
THPO P40225 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
ALDH1A1 P00352 1/20 0.39
MTNR1A P48039 9/20 0.39
MTNR1B P49286 9/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1812110 0.81 SMN1; SMN2 (0.42) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL4028312 0.81 SMN1; SMN2 (0.42) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL24866254 0.81 SMN1; SMN2 (0.42) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL24864285 0.80 KDM4E (0.45) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL12064029 0.80 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL12064309 0.80 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL12064041 0.80 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL23451094 0.78 MAPT (0.59) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL13611402 0.78 MAPT (0.59) KDM4ESMN1; SMN2MAPTTHRBALOX15
SCHEMBL4659641 0.78 SMN1; SMN2 (0.43) KDM4ESMN1; SMN2MAPTTHRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 KDM4E 2891/4885SMN1; SMN2 2456/4885MAPT 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.